
Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in this application.

- 1. (currently amended) A chimeric, humanized or human antibody that competitively inhibits binding of an amphiregulin polypeptide to an anti-amphiregulin antibody, wherein the amphiregulin polypeptide comprises consists essentially of SEQ ID NO: 1, and wherein the anti-amphiregulin antibody comprises a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 12 and a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 5 and 14 and the anti-amphiregulin antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 12, and 14.
- 2. (cancelled)
- 3. (previously presented) The antibody of claim 1, wherein the anti-amphiregulin antibody is selected from the group consisting of: an antibody comprising SEQ ID NO: 2 and SEQ ID NO: 3; an antibody comprising SEQ ID NO: 4 and SEQ ID NO: 5; and an antibody comprising SEQ ID NO: 12 and SEQ ID NO: 14.
- (previously presented) The antibody of claim 1, wherein the antibody comprises SEQ ID NO:
 12 and SEQ ID NO: 14.
- 5. (original) The antibody of claim 1, wherein the antibody is an antibody fragment.
- 6. (original) The antibody of claim 5, wherein the antibody fragment is selected from the group consisting of Fab, Fab', F(ab')₂, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.
- 7. (original) The antibody of claim 1, wherein the antibody is conjugated to an effector moiety.
- 8. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a cancer cell.

- 9. (previously presented) The antibody of claim 1, wherein the amphiregulin polypeptide is on a skin cell.
- 10. (currently amended) A chimeric, humanized or human antibody comprising a heavy chain variable region having an amino acid sequence of at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 12, and a light chain variable region having an amino acid sequence of at least 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 3, 5 and 14.
- 11. (cancelled)
- 12. (cancelled)
- 13. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1.
- 14. (original) The pharmaceutical composition of claim 13, wherein the antibody is conjugated to an effector moiety.
- 15. (original) The pharmaceutical composition of claim 13, wherein the antibody comprises SEQ ID NO: 12 and SEQ ID NO: 14.
- 16. (cancelled)
- 17. (cancelled)
- 18. (currently amended) A chimeric, humanized or human antibody that specifically binds to a <u>an amphiregulin</u> polypeptide, wherein the <u>amphiregulin</u> polypeptide <u>comprises consists</u> <u>essentially of SEQ ID NO: 1, and wherein the antibody binds to the same amphiregulin epitope as that bound by an antibody selected from the group consisting of: an antibody comprising a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5; and an antibody comprising a heavy chain variable region of SEQ ID NO: 14.</u>

- 19. (cancelled)
- 20. (previously presented) The antibody of claim 18, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂, Fv fragments, rIgG, diabodies, single chain antibodies and multispecific antibodies.
- 21. (previously presented) The antibody of claim 18, wherein the antibody inhibits proliferation of tumor cells.
- 22. (previously presented) The antibody of claim 18, wherein the antibody inhibits *in vivo* proliferation of tumor cells that express amphiregulin.
- 23. (previously presented) The antibody of claim 18, wherein the antibody neutralizes at least one biological activity of amphiregulin.
- 24. (previously presented) The antibody of claim 18, wherein the antibody is conjugated to an effector moiety.
- 25. (previously presented) The antibody of claim 18, wherein the antibody competes for binding to the ligand binding site of a ligand of amphiregulin.
- 26. (cancelled)
- 27. (cancelled)
- 28. (previously presented) A hybridoma producing the antibody of claim 18.
- 29. (cancelled)
- 30. (cancelled)
- 31. (cancelled)
- 32. (currently amended) A polypeptide comprising a <u>an amino acid</u> sequence selected from <u>the</u> group consisting of SEQ ID NOs: 2, 3, 4, 5, 12 and 14.



44. (cancelled)

45. (cancelled)

- 46. (new) A chimeric, humanized or human antibody that specifically binds to a polypeptide consisting of SEQ ID NO: 1.
- 47. (new) The antibody of claim 46, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 3.
- 48. (new) The antibody of claim 46, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 5.
- 49. (new) The antibody of claim 46, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.